SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (358)12/21/1999 6:59:00 PM
From: LLCF  Read Replies (1) | Respond to of 1834
 
<A smidge of cash >

I think the company may be wise to float a secondary here.... JMO of course. This would keep our dream alive of huge upside and independence.

DAK



To: scaram(o)uche who wrote (358)12/21/1999 8:40:00 PM
From: WTDEC  Read Replies (2) | Respond to of 1834
 
Rick,

IMO, the sale to Paladin underscores Gary Lyons' focus on building stockholder value as well as on great drugs. It would have been easy to keep neurosteroids and build the 'research empire' either now or later on. Instead, he recognized retaining it would drain resources and dilute stockholder value.

Best regards,

Walter


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News